Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer

Drugs

Volumn 57, Issue 2, 1999, Pages 133-155

  Hoekman, Klaas ^a   Van der Vijgh, Wim J F ^a   Vermorken, Jan B ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; AMIFOSTINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DIETHYLDITHIOCARBAMIC ACID; FLAVONOID; GLUTATHIONE; MESNA; PLATINUM DERIVATIVE; RADIOPROTECTIVE AGENT; RAZOXANE; SODIUM THIOSULFATE;

ARTICLE; CANCER; CANCER CELL CULTURE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROTECTION; CYTOTOXICITY; GASTROINTESTINAL TOXICITY; GONAD DYSFUNCTION; LIVER TOXICITY; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; TURNOVER TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOPROTECTION; DRUG TOXICITY; HUMANS; NEOPLASMS; RADIOTHERAPY;

EID: 0032973059     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00002     Document Type: Article

References (214)

1. Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol/ Oncol Clin North Am 1996; 10: 967-90
2. Muggia FM. Cytoprotection: concepts and challenges. Support Care Cancer 1994; 2: 377-9
3. Lewis C. A review of chemoprotectants in cancer chemotherapy. Drug Saf 1994; 11: 153-62
4. Schuchter LM, Luginbuhl WE, Mcropol NJ. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742-51
5. Loprinzi CL, Foote RL, Michalak J. Alleviation of cytotoxic therapy-induced normal tissue damage. Semin Oncol 1995; 22: 95-7
6. Houba PHJ, Leenders RGG, Boven E, et al. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 1996; 52: 455-63
7. Steehl GG. Basic clinical radiobiology. London: Edward Arnold, 1993
8. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994; 65: 27-33
9. Szumiel I. Review: ionizing radiation-induced cell death. Int J Radiat Biol 1994; 66: 329-41
10. Rubin P, Johnston CJ, Williams JP, et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 1995; 33: 99-109
11. Busch DB. Radiation and chemotherapy injury: pathophysiology, diagnosis, and treatment. Crit Rev Oncol Hematol 1993; 15: 49-89
12. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845-53
13. Hoekman K, Vermorken JB. Incidence and prevention of non-hematological toxicity of high-dose chemotherapy. Ann Med 1996; 28: 175-82
14. Spangrude GJ. Biological and clinical aspects of hematopoietic stem cells. Ann Rev Med 1994; 45: 93-104
15. Mauch P, Costine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31: 1319-39
16. MacManus M, Lamborn K, Khan W, et al. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood 1997; 89: 2303-10
17. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 1992; 19: 566-79
18. Holland HK, Dix SP, Geller RB, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-64
19. Wilmore DW. Metabolic support of the gastrointestinal tract. Cancer 1997; 79: 1794-803
20. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529-42
21. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-7
22. Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med 1991; 324: 843-5
23. Billingham ME, Mason JW, Bristow MR, et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865-72
24. Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure by anthracycline chemotherapy. Cancer 1992; 70: 2637-41
25. Schwartz RG, McKenzie WD, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-18
26. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1996; 13: 2688-99
27. Hellman K. Anthracycline cardiotoxicity prevention by dexrazoxane: break-through of a barrier - sharpens antitumor profile and therapeutic index. J Clin Oncol 1996; 14: 332-3
28. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1704-12
29. Rubin P, Petros W, Vredenbirgh J, et al. Cyclophosphamide-induced cardio-myopathy following high-dose chemotherapy. Proc Am Soc Clin Oncol 1995; 14: 326
30. Postma TJ, Benard BA, Huijgens PC, et al. Long term effects of vincristine on the peripheral nervous system. J Neurooncol 1993; 15: 23-7
31. Postma TJ, Heimans JJ. Chemotherapy-induced neuropathy. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Neuro-Oncology, Pt II. Vol. 25. Elsevier: Amsterdam, 1997: 1-21
32. Boer HH, Moorer-van Felft CM, Müller LJ, et al. Ultrastructural neuropathologic effects of taxol on neurons of the fresḧwater snail Lymnaea stagnalis. J Neurooncol 1995; 25: 49-57
33. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368-73
34. Jerian SM, Sarosy GA, Link CJ, et al. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol Oncol 1993; 51: 277-80
35. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241-8
36. 3H-taxol in the nervous system and organs of rats. Proc Am Soc Clin Oncol 1993; 11: 160
37. Hamers FPT, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer 1991; 27: 372-6
38. Boogerd W. Neurological complications of chemotherapy. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Vol. 21 (65). Elsevier: Amsterdam, 1995: 527-46
39. Warner E. Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995; 5: 161-9
40. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995; 6: 369-83
41. Thompson SW, David LE, Kornfeld M, et al. Cisplatin neurotoxicity: clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 1984; 54: 1269-75
42. Cavaletti G, Bogliun G, Marzorati L, et al. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 1994; 14: 1287-92
43. Watkin SW, Husband DJ, Green JA, et al. Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 1989; 25: 1303-10
44. Cerny T, Küpfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992; 3: 679-81
45. Schweitzer VG. Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am 1993; 26: 759-89
46. Rybak LP. Ototoxicity. Curr Opin Otolaryngol Head Neck Surg 1996; 4: 302-7
47. Vermorken JB, Kapteijn TS, Hart AAM, et al. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 19: 53-8
48. Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platin ototoxicity in children. Laryngoscope 1991; 101: 917-24
49. Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995; 16: 731-40
50. Ravi R, Somani S, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995; 76: 386-94
51. Neuwelt EA, Brummett RE, Muldoon LL, et al. Sodium thiosulfate as a protectant against carboplatin-induced ototoxicity in the treatment of patients with malignant brain tumors. Proc Am Soc Clin Oncol 1997; 16: 393
52. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992; 19: 521-8
53. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 1989; 25: 1-9
54. Recce PA, Stafford I, Russel J, et al. Reduced ability to clear ultrafiltrable platinum with repeated courses of cisplatin. J Clin Oncol 1986; 4: 1392-8
55. Beyer J, Rick O, Weinknecht S, et al. Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Bone Marrow Transplant 1997; 20: 813-9
56. Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12: 159-65
57. Sleijfer S, Vujaskovic Z, Limburg PC, et al. Induction of tumor necrosis-alpha as a cause of bleomycin-related toxicity. Cancer 1998; 82: 970-4
58. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11: 1-20
59. Lazo JS, Dale GH. The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents. Cancer Treat Rev 1990; 17: 165-7
60. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophophamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-7
61. Schmitz N, Diehl V. Carmustine and the lungs. Lancet 1997; 349: 1712-3
62. Okuno SH, Frytak S. Mitomycin lung toxicity-acute and chronic phases. Am J Clin Oncol 1997; 20: 282-4
63. Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Resp Crit Care Med 1998; 157: 565-73
64. Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-8
65. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemeitabine. Cancer 1997; 80: 286-91
66. Rizzi V, Cioschi B, Cartei G, et al. Liver function tests and lidocaine metabolism (MEGX test) during iv CMF therapy in breast cancer. Anticancer Drugs 1996; 7: 846-50
67. Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729-36
68. Barton C, Waxman J. Effects of chemotherapy on fertility. Blood Rev 1990; 4: 187-95
69. Reichman BS, Green KB. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst 1994; 16: 125-9
70. Meistrich ML. Effects of chemotherapy and radiotherapy on spermatogenesis. Eur Urol 993; 23: 136-42
71. Stephenson WT, Poirier SM, Rubin L, et al. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995; 13: 2278-80
72. Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1998; 15: 239-45
73. Spencer CM, Goa KL. Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50: 1001-31
74. Onishi ST, Onishi T, Click JH, et al. In vitro study on the antioxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 1992; 33: 419
75. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, et al. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethylthiocarbamate. Biochem Pharmacol 1992; 43: 1013-9
76. Grdina DJ, Shigematsu N, Dale P, et al. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anticytotoxic and antimutagenic mechanisms of action. J Carcinogenesis 1995; 16: 767-74
77. Kataoka Y, Perrin J, Hunter N, et al. Antimutagenic effects of amifostine: clinical implications. Semin Oncol 1996; 23 Suppl. 8: 53-7
78. Treskes M, Boven E, Holwerda U, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992; 52: 2257-60
79. Treskes M, Boven E, van de Loosdrecht AA, et al. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30A: 183-7
80. Romanuel FCA, Bannister RG. Localized areas of high alkaline phosphatase activity in endothelium of arteries. Nature 1962; 195: 611-2
81. Walker EM, Gale GR. Methods of reduction of cisplatin nephrotoxicity. Ann Clin Lab Sci 1981; 11: 397-410
82. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. Cancer Res 1980; 40: 1519-24
83. Newton GL, Aguilera JA, Kim T, et al. Transport of aminothiol radioprotectors into mammalian cells: passive diffusion versus mediated uptake. Radiat Res 1996; 146: 206-15
84. Treskes M, Holwerda U, Klein I, et al. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 1991; 42: 2125-30
85. Korst AEC, Boven E, van der Sterre MLT, et al. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Br J Cancer 1997; 75: 1439-46
86. Korst AEC, van der Sterre MLT, Eeltink CM, et al. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors. Clin Cancer Res 1997; 3: 697-703
87. Korst AEC, van der Sterre MLT, Gall HE, et al. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 1997; 4: 331-6
88. Hasinoff BB. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis (3,5-dioxopiperazinyl-1-yl) propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe (III) and Cu (II) complexes of adriamycin. Agents Actions 1990; 29: 374-81
89. Herman EH, Wiliak DT, Hellman K, et al. Biological properties of ICR-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 1982; 19: 249-90
90. Tanabe K, Ikegami Y, Ishida R, et al. Inhibition of topoisomerase II by antitumor agent bis-(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8
91. Woodman RJ. Enhancement of antitumor effectiveness of ICRF-159 against early L1210 leukemia by combination with cis diamminodichloroplatinum or daunomycin. Cancer Chemother Rep 2 1974; 4: 45-52
92. Sehested M, Jensen PB, Sorensen BS, et al. Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46: 389-93
93. Sorensen B, Bastholt L, Mirza MR, et al. The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. Cancer Chemother Pharmacol 1994; 34: 439-43
94. Reedijk J. Improved understanding in platinum and in tumor chemistry. Chem Comm 1996; 801-6
95. Ishikawa T, Ali-Osman F. Glutathione associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells: molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25
96. Leone R, Fracasso ME, Soresi E, et al. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 1992; 29: 385-90
97. Cascinu S, Cordella L, del Ferro E, et al. Neuro-protective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995; 13: 26-32
98. Lauterberg BH, Nguyen T, Hartmann B, et al. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 1994; 35: 132-6
99. Hahn R, Wendel A, Flohé L. The fate of extracellular glutathione in the rat. Biochem Biophys Acta 1978; 539: 324-37
100. Blair SL, Heerdt P, Sachar S, et al. Glutathione metabolism in patients with non-small cell lung cancers. Cancer Res 1997; 57: 152-5
101. Bai F, Nakanishi M, Kawasaki M, et al. Immunohistochemical expression of glutathione S-transferase-p can predict chemotherapy response in patients with non-small cell lung cancer. Cancer 1996; 78: 416-22
102. Hamers FPT, Brakkee JH, Cavalletti E, et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544-9
103. Elferink F, van der Vijgh WJF, Klein I, et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem 1988; 32: 641-5
104. Goel R, Creary SM, Horton C, et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 1989; 81: 1552-60
105. van Rijswijk REN, Hockman K, Burger CW, et al. Experience with intraperitoneal cisplatin and etoposide and i.v. thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann Oncol 1997; 8: 1235-41
106. Pleifle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985; 3: 237-44
107. Bryant BM, Jarman M, Ford HT, et al. Prevention of ifosfamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980; II: 657-9
108. Li GC, Brock N, Li JQ, et al. Treatment of advanced malignancies with ifosfamide under protection with mesna. Int J Clin Pharmacol Res 1988; 8: 55-67
109. Goodman TL, McKenna LM, Li JT, et al. Clinical pharmacology and efficacy of mesna given po to outpatients treated with ifosfamide for solid tumours. Proc Am Soc Clin Oncol 1992; 11: 113
110. Bodenner DL, Dedon PC, Keng PC, et al. Selective protection against cis-diamminedichloroplatinum (II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate (DDTC). Cancer Res 1986; 46: 2751-5
111. Berry JM, Jacobs C, Sikic B, et al. Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 1990; 9: 1585-90
112. Francis P, Markman M, Hakes T, et al. Diethyldithiocarbamate chemo-protection of carboplatin-induced hematological toxicity. J Cancer Res Clin Oncol 1993; 119: 360-2
113. Gandara DR, Nahhas WA, Adelson MD, et al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicity. J Clin Oncol 1995; 13: 490-6
114. van Acker SABE, Voest EE, Beems RB, et al. Cardioprotective properties of O-(b-hydroxyethyl)-rutosides in doxorubicin pretreated BALB/c mice. Cancer Res 1993; 53: 4603-7
115. Hüsken BCP, de Jong J, Beekman B, et al. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother Pharmacol 1995; 37: 55-62
116. van Acker SABE, Tromp MNJL, Haenen GRMM, et al. Flavonoids as scavengers of nitric oxide radicals. Biochem Biophys Res Commun 1995; 214: 755-9
117. van Acker SABE, Boven E, Kuiper K, et al. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the anti-tumor activity of doxorubicin. Clin Cancer Res 1997; 3: 1747-54
118. De Koning P, Neijt JP, Jennekens FGI, et al. ORG 2766 protects from cisplatin-induced neurotoxicity in rats. Exp Neurol 1987; 97: 746-50
119. Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44: 488-94
120. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94
121. van Gerven JMA, Hovestadt A, Moll JWB, et al. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 1994; 241: 432-5
122. Hovestadt A, van der Burg MEL, Verbiest HBC, et al. The course of neuropathy after cessation of cisplatin treatment, combined with ORG 2766 or placebo. J Neurol 1992; 239: 143-6
123. Heimans JJ, van Kooten B, van Diemen HAM, et al. The influence of an ACTH (4-9) analogue on vinca alkaloid-induced neuropathy. Neurology 1992; 42: 369
124. Hamers FP, Pette C, Neijt JP, et al. The ACTH-(4-9) analog ORG-2766 prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993; 233: 177-8
125. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995; 7: 304-9
126. Berry G, Billingham M, Alderman E, et al. Reduced cardiotoxicity of doxil (pegylated liposomal doxorubicin) in Aids Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proc Am Soc Clin Oncol 1996; 15: 303
127. Jablonowski H, Boden D, Häussinger D. Long term use of DOX-SL™ (Stealth® liposomal doxorubicin HCI) in the treatment of moderate to severe Aids-related Kaposi's sarcoma. Proc Am Soc Clin Oncol 1996; 15: 303
128. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27
129. Rosenfeld C, Weisberg S, York RM, et al. Prevention of adriamycin® cardiomyopathy with dexrazoxane (ADR-529, ICRF-187). Proc Am Soc Clin Oncol 1992; 11: 62
130. Weisberg SR, Rosenfeld CS, York RM, et al. Dexrazoxane (ADR-529, ICRF-187, Zinecard®) protects against doxorubicin induced chronic cardiotoxicity. Proc Am Soc Clin Oncol 1992; 11: 91
131. Maillard JA, Speyer JL, Hanson K, et al. Prevention of chronic adriamycin® cardiotoxicity with the bisdioxopiperazine dexrazoxane (ICRF-187, ADR-529, Zinecard®) in patients with advanced metastatic breast cancer. Proc Am Soc Clin Oncol 1992; 11: 91
132. Swain SM, Whaley FS, Gerber Mc, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32
133. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-20
134. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent, ICRF-187, in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-72
135. Swain SM, Whaley FS, Gerber Mc, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-40
136. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15
137. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43
138. Schüller J, Czejka M, Pietrzak C, et al. Doxorubicin pharmacokinetics is altered differently by the cytoprotective agents amifostine or cardioxane (ICRF 187) [abstract]. Ann Oncol 1996; 7 Suppl. 5: 124
139. Basser RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994; 12: 1659-66
140. de Graaf H, van der Graaf WTA, Dolsma WV, et al. Evaluation of cardiotoxicity and pulmonary toxicity after high-dose chemotherapy with ABMT or PSCT and radiotherapy in breast cancer patients. Proc Am Soc Clin Oncol 1996; 15: 334
141. Rasey JS, Krohn KA, Menard TW, et al. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys 1986; 12: 1487-90
142. Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro. Eur J Cancer 1996; 32A: S21-5
143. Bhanumathi P, Saleesh EB, Vasudevan DM. Creatinine phosphokinase and cardiotoxicity in adriamycin chemotherapy and its modification by WR-1065. Biochem Arch 1992; 8: 335-8
144. van Acker SABE, Kramer K, Grimbergen JA, et al. Monohydroxyethylrutoside as protector against chronic doxorubicin induced cardiotoxicity. Br J Pharm 1995; 115: 1260-4
145. van Acker SABE, Kramer K, Vuest EE, et al. Doxorubicin induced cardiotoxicity monitored by ECG in freely moving mice: a new model to test potential protectors. Cancer Chemother Pharmacol 1996; 38: 95-101
146. Chraibi Y, Fernandez A, Drozl JP, et al. A randomized double blind, placebo controlled study of ORG 2766, an ACTH (4-9) analogue, for the prevention of neuropathy induced by cisplatin with or without vinca-alkaloids combination chemotherapy. Eur J Cancer 1993; 29A; 206
147. Neijt J, van der Burg M, Vecht C, et al. A double-blind randomised study with ORG-2766, an ACTH (4-9) analog, to prevent cisplatin neuropathy. Proc Am Soc Clin Oncol 1994; 13: 261
148. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin ± reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 415-9
149. Colombo N, Bini S, Miceli D, et al. Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 1995; 5: 81-6
150. Müller LJ, Moorer-van Delft CM, Treskes M, et al. Properties of WR2721 (Ethiofos) as modulator of cisplatin-induced neurotoxicity studied at the ultrastructural level in the pond snail Lymnaea stagnalis. Int J Oncol 1993; 2: 701-10
151. Mollman JE. Protection against cisplatin-neurotoxicity in cultured dorsal root ganglion cells by WR 2721. 7th Conference on Chemical Modifiers of Cancer Treatment; 1991 Feb 2-5; Clearwater (FL): 328-9
152. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
153. Planting AST, Vermorken JB, Catimel G, et al. Randomized phase II study of weekly cisplatin with or without amifostine in patients with advanced head and neck cancer. Eur J Cancer 1995; 31A: S5
154. Schuchter L, DiPaola R, Greenberg R, et al. A phase I study of amifostine and escalating doses of taxol in patients with advanced cancer. Eur J Cancer 1995; 31A Suppl.: S199
155. Hayakawa K, Sobue G, Itoh T, et al. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol on adult rat sympathetic ganglion explants in vitro. Life Sci 1994; 55: 519-25
156. Apfel SC, Lipton RB, Arezzo JC, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991; 29: 87-90
157. Küpfer A, Aeschlimann C, Wermuth B, et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343: 763-4
158. Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 1996; 56: 706-9
159. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cisdichloro-diammineplatinum(II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 1980; 64: 57-64
160. Glover D, Grabelsky S, Fox K, et al. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 1989; 16: 1201-4
161. Millar JL, McElwain TJ, Clutterbuck RD, et al. The modification of melphalan toxicity in tumor bearing mice by S-2-(3 aminopropylamino)-ethyl-phosphorothioic acid (WR-2721). Am J Clin Oncol 1982; 5: 321-8
162. Valeriole F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330-1
163. Wasserman TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 1981; 4: 3-6
164. List AF, Heaton R, Glinsman-Gibson B, et al. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996; 23 Suppl. 8: 58-63
165. Shpall EJ, Stemmer SM, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-7
166. Cagnoni PJ, Jones RB, Bearman SI, et al. Use of amifostine in bone marrow purging. Semin Oncol 1996; 23 Suppl. 8: 44-8
167. van der Wilt CL, van Laar JAM, Gyergyay F, et al. Biochemical modification of the toxicity and the anti-tumour effect of 5 fluorouracil and cisplatinum by WR-2721 in mice. Eur J Cancer 1992; 28A: 2017-24
168. van Laar JAM, van der Wilt CL, Treskes M, et al. Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1992; 31: 97-102
169. Mazur L, Czyzewska A. Inhibition of the clastogenic effect of cyclophosphamide by WR-2721 in the bone marrow of mice. Mutat Res 1994; 309: 219-23
170. Budd GT. Amifostine and chemotherapy-related thrombopenia. Semin Oncol 1996; 23 Suppl. 8: 49-52
171. Glover DJ, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-8
172. Poplin EA, Lorusso P, Lokich JJ, et al. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994; 33: 415-9
173. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134-40
174. Patchen ML, MacVittie TJ, Souza LM. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int J Radiat Oncol Biol Phys 1992; 22: 773-9
175. Patchen ML, MacVittie TJ. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 1994; 21: 26-32
176. Patchen ML. Amifostine plus granulocyte colony-stimulating factor therapy enhances recovery from supralethal radiation exposures: preclinical experience in animal models. Eur J Cancer 1995; 31A Suppl.: S17-21
177. Symonds RP. Treatment-induced mucositis: an old problem with new remedies. Br J Cancer 1998; 77: 1689-95
178. Giedler NM, McGurk M, Aqual S, et al. The effect of epidermal growth factor mouthwash on cytotoxic-induced oral ulceration. Am J Clin Oncol 1995; 18: 403-6
179. Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92: 481-4
180. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluouracil-induced stomatitis by oral eryotherapy. J Clin Oncol 1991; 9: 449-52
181. Sartori S, Trevisani L, Noelsen I, et al. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. Cancer 1996; 78: 1477-82
182. Keith JC, Albert L, Sonis ST, et al. IL-11, a pleiotrophic cytokine: exciting new effects of IL-11 on gastro-intestinal mucosal biology. In: Murphy MJ, editor. Polyfunctionality of hematopoietic regulators. Dayton (OH): AlphaMed Press, 1994: 79-90
183. Orazi A, Du X, Yang Z, et al. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 1996; 75: 33-42
184. Wilmore DW. Metabolic support of the gastrointestinal tract. Cancer 1997; 79: 1794-803
185. Klimberg VS, Souba WW, Dolson DJ, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990; 66: 62-8
186. Skubitz KM, Anderson PM. Oral glutamine to prevent chemotherapy induced stomatitis. J Lab Clin Med 1996; 127: 223-8
187. Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation: a randomized, double-blind, controlled trial. Ann Intern Med 1992, 116: 821-8
188. Capizzi RL. The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®). Eur J Cancer 1996; 32A Suppl. 4: S5-16
189. Nakamura J, Shaw LM, Brown DQ. Hydrolysis of WR-2721 by mouse liver cell fractions. Radiat Res 1987; 109: 143-52
190. Fiorentini G, Cariello A, Giovanis P, et al. Amifostine as modulator of hepatic (HT) and biliary toxicity (BT) from intra-arterial hepatic chemoembolization (IAHC): results of a phase I study. Ann Oncol 1998; 9 Suppl. 2: 55
191. Herman EH, Hasinoff BB, Zhang J, et al. Morphologic and morphogenetic evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology 1995; 98: 163-75
192. Allalunis-Turner MJ, Siemann DW. Modification of cyclophosphamide-induced pulmonary toxicity in normal mice. NCI Monogr 1988; 51-3
193. Wang LM, Wang QW, Fernandes DJ, et al. Amifostine protects MRC-5 human
194. Sugahara K, Iyama K, Sakanashi Y, et al. Keratinocyte growth factor (KGF) prevents bleomycin-induced lung fibrosis in rats. Mol Biol Cell 1995; 6 Suppl.: 203a
195. Chap L, Shpiner R, Levine M, et al. Pulmonary toxicity of high-dose chemotherapy for breast cancer a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997; 20: 1063-7
196. Manabe F, Takeshima H, Akaza H. Protecting spermatogenesis from damage induced by doxorubicin using the luteinizing hormone-releasing hormone agonist leuprorelin. Cancer 1997; 79: 1014-21
197. Milas LD, Murray AW, Brock WA, et al. Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio. Pharmacol Ther 1988; 39: 179-87
198. Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivates: form of the drug responsible for protection. Cancer Res 1988; 48: 3641-7
199. Sigdestad CP, Connor AM, Scott RM. The effect of S-2-(3 amino-propylamino)-ethylphosphorothioic acid (WR-2721) on intestinal crypt survival. Radiat Res 1975; 62: 267-75
200. Down JD, Laurent GJ, McAnulty RJ, et al. Oxygen-dependent protection of radiation lung damage in mice by WR 2721. Int J Radiat Biol Relat Stud Phys Chem Med 1984; 46: 597-607
201. Sodicoff M, Conger AD, Trepper P, et al. Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res 1978; 75: 317-26
202. Sodicoff M, Conger AD, Pratt NE, et al. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res 1978; 76: 172-9
203. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69: 2820-5
204. Montana GS, Anscher MS, Mansbach CM, et al. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis: a phase I/II trial. Cancer 1992; 69: 2826-30
205. Mitsuhashi N, Takahashi I, Takahashi M, et al. Clinical study of radioprotective effects of amifostine (YM-08310, WR 2721) on long-term outcome for patients with cervical cancer. Int J Radiat Oncol Biol Phys 1993; 26: 407-11
206. Wadler S, Beitler J, Rubin JS, et al. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group Study. J Clin Oncol 1993; 11: 1511-6
207. Niibe H, Takahashi I, Mitsuhashi N, et al. An evaluation of the clinical usefulness of amifostine (YM-08310), a radioprotective agent. J Jpn Soc Cancer Ther 1985; 20: 984-93
208. McDonald S, Meyerowitz C, Smudain T, et al. Amifostine preserves salivary gland dysfunction during irradiation of the head and neck. Int J Radiat Oncol Biol Phys 1995; 31 Suppl. 5: 415
209. Brizel D, Sauer R, Wannenmacher M, et al. Randomized phase III trial of radiation ± amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 1487
210. Büntzel J, Küttner K, Fröhlich D, et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 1998; 9: 505-9
211. Giglio R, Mickiewicz E, Pradier E, et al. Alternating chemotherapy (CT) + radiotherapy (RT) with amifostine (A) protection for head and neck cancer (HN): early stop of a randomized trial. Proc Am Soc Clin Oncol 1997; 16: 384
212. Tannehill SP, Mehta MP, Larson M, et al. Phase II clinical trial of amifostine (WR-2721), cisplatin, vinblastine and thoracic radiation therapy for unresectable stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1995; 32 Suppl. 1: 196
213. Tannehill SP, Mehta MP. Amifostine and radiation therapy: past, present, and future. Semin Oncol 1996; 23 Suppl. 8: 69-77
214. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-80